Figure 2From: Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm ruptureConfirmation of the changes of CSF sAxl levels in both discovery and validation cohorts using ELISA. (A) sAxl concentration in individual CSF samples from the discovery cohort (n = 10 per group). (B) sAxl concentration in individual CSF samples from the validation cohort (n = 20 per group). *p <0.05 and **p <0.01 (Newman-Keuls test). Error bars represent the 95% confidence interval of the mean.Back to article page